Amylyx Pharmaceuticals Etf Analysis

Amylyx Etf Analysis Notes

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis and other neurodegenerative diseases. Amylyx Pharmaceuticals is listed under Biotechnology in the United States and is traded on NASDAQ Exchange exchange. For more info on Amylyx Pharmaceuticals please contact Justin Klee at 617 682 0917 or go to https://amylyx.com.

Amylyx Pharmaceuticals Investment Alerts

Amylyx Pharmaceuticals Upcoming and Recent Events

Amylyx Stock Institutional Investors

Note, although Amylyx Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Amylyx Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 286.53 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Amylyx Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Amylyx Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Amylyx Profitablity

The company has Profit Margin (PM) of (1.32) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (181.88) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $181.88.

Management Efficiency

Amylyx Pharmaceuticals has return on total asset (ROA) of (0.4344) % which means that it has lost $0.4344 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8443) %, meaning that it created substantial loss on money invested by shareholders. Amylyx Pharmaceuticals' management efficiency ratios could be used to measure how well Amylyx Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.

Top Amylyx Pharmaceuticals Etf Constituents

Technical Drivers

As of the 18th of December 2024, Amylyx Pharmaceuticals shows the Downside Deviation of 5.3, risk adjusted performance of 0.1208, and Mean Deviation of 4.38. Amylyx Pharmaceuticals technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the entity's future prices.

Amylyx Pharmaceuticals Price Movement Analysis

Amylyx Pharmaceuticals Insider Trading Activities

Amylyx Pharmaceuticals Outstanding Bonds

Amylyx Pharmaceuticals Predictive Daily Indicators

Amylyx Pharmaceuticals Forecast Models

Amylyx Pharmaceuticals' time-series forecasting models are one of many Amylyx Pharmaceuticals' etf analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Amylyx Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Etf analysis is the technique used by a trader or investor to examine and evaluate how Amylyx Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Amylyx shares will generate the highest return on investment. We also built our etf analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Etf such as Amylyx Pharmaceuticals. By using and applying Amylyx Etf analysis, traders can create a robust methodology for identifying Amylyx entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Amylyx analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Amylyx analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Amylyx Pharmaceuticals etf analysis indicators help investors evaluate how Amylyx Pharmaceuticals etf reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Amylyx Pharmaceuticals shares will generate the highest return on investment. By understating and applying Amylyx Pharmaceuticals etf analysis, traders can identify Amylyx Pharmaceuticals position entry and exit signals to maximize returns.

Amylyx Pharmaceuticals financial ratios help investors to determine whether Amylyx Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Amylyx with respect to the benefits of owning Amylyx Pharmaceuticals security.